ScholarGate
Assistent

Compara mètodes

Revisa els mètodes seleccionats l'un al costat de l'altre; les files que difereixen es ressalten.

Anàlisi de Bioequivalència (Dues Proves Unilaterals)×Model Emax: Anàlisi Farmacodinàmica de la Relació Dos-Resposta×
CampFarmacometriaFarmacometria
FamíliaHypothesis testRegression model
Any d'origen19871981
Autor originalDonald J. SchuirmannHolford & Sheiner
TipusParametric equivalence testNonlinear dose-response regression model
Font seminalSchuirmann, D. J. (1987). A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics, 15(6), 657–680. DOI ↗Holford, N. H. G., & Sheiner, L. B. (1981). Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clinical Pharmacokinetics, 6(6), 429–453. DOI ↗
ÀliesTOST Procedure, Average Bioequivalence, BE Analysis, Biyoeşdeğerlik AnaliziMaximum Effect Model, Hyperbolic Emax Model, Sigmoidal Emax Model, Emax Farmakodynamik Modeli
Relacionats22
ResumBioequivalence Analysis is a regulatory-grade statistical framework used to determine whether a test drug formulation (generic or reformulated) delivers the active ingredient to the systemic circulation at a rate and extent comparable to a reference product. Introduced by Donald J. Schuirmann in 1987, the method operationalizes equivalence through the Two One-Sided Tests (TOST) procedure, replacing the ambiguous absence-of-difference paradigm with an explicit equivalence margin evaluated on log-transformed pharmacokinetic endpoints such as AUC and C_max.The Emax model is a nonlinear pharmacodynamic model that describes the relationship between drug concentration and biological effect. Introduced by Holford and Sheiner in 1981, it characterizes dose-response curves using three fundamental parameters: the maximum achievable effect (Emax), the concentration producing half-maximal effect (EC50), and an optional baseline effect (E0). It remains the standard framework in clinical pharmacology and drug development for quantifying pharmacodynamic dose-response relationships.
ScholarGateConjunt de dades
  1. v1
  2. 1 Fonts
  3. PUBLISHED
  1. v1
  2. 1 Fonts
  3. PUBLISHED

Ves a la cerca Baixa les diapositives

ScholarGateCompara mètodes: Bioequivalence Analysis · Emax Model. Recuperat el 2026-06-20 de https://scholargate.app/ca/compare